Citizens Jmp Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $152.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective trimmed by Citizens Jmp from $176.00 to $152.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a market outperform rating on the stock.

RYTM has been the subject of several other reports. Telsey Advisory Group set a $143.00 target price on shares of Rhythm Pharmaceuticals in a research report on Thursday, March 12th. Stifel Nicolaus set a $131.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, February 26th. Morgan Stanley dropped their price objective on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a report on Tuesday. Needham & Company LLC cut their target price on shares of Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, UBS Group reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $131.13.

Rhythm Pharmaceuticals Stock Up 5.2%

NASDAQ:RYTM opened at $90.31 on Tuesday. The stock has a market cap of $6.17 billion, a P/E ratio of -29.04 and a beta of 2.06. The business’s 50-day moving average price is $99.31 and its two-hundred day moving average price is $102.60. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.06. The company had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.Rhythm Pharmaceuticals’s revenue was up 36.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.72) earnings per share. On average, equities research analysts expect that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Activity

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer directly owned 160 shares of the company’s stock, valued at approximately $14,329.60. This trade represents a 97.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,267 shares of company stock valued at $2,719,955 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RYTM. AQR Capital Management LLC boosted its position in Rhythm Pharmaceuticals by 148.2% during the 1st quarter. AQR Capital Management LLC now owns 39,363 shares of the company’s stock valued at $2,085,000 after buying an additional 23,506 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Rhythm Pharmaceuticals by 6.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,282 shares of the company’s stock worth $1,874,000 after acquiring an additional 2,126 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Rhythm Pharmaceuticals by 25.6% in the second quarter. Bank of New York Mellon Corp now owns 184,109 shares of the company’s stock valued at $11,634,000 after acquiring an additional 37,524 shares during the period. Savant Capital LLC purchased a new position in shares of Rhythm Pharmaceuticals in the second quarter valued at about $277,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of Rhythm Pharmaceuticals by 22.7% during the second quarter. PNC Financial Services Group Inc. now owns 5,543 shares of the company’s stock valued at $350,000 after acquiring an additional 1,025 shares during the last quarter.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approval for a new indication — The FDA approved IMCIVREE® (setmelanotide) for patients with acquired hypothalamic obesity, making it the first and only approved therapy for this rare, difficult‑to‑treat condition; this expands the commercial opportunity and is the primary catalyst for the stock rally today. FDA Approval Release
• Positive Sentiment: Some broker price targets remain elevated — An American Banking News aggregation shows broker price targets (one cited at $133.19), which supports upside narratives among buy‑side holders. Broker PT Coverage
• Neutral Sentiment: HC Wainwright trims price target but keeps a Buy — HC Wainwright lowered its PT to $100 (from $110) and continues to rate RYTM a Buy, which tempers the bullish view though still implying upside from current levels. Coverage Note
• Neutral Sentiment: Valuation commentary after share weakness — Coverage pieces are reassessing valuation given recent volatility and long‑term returns; useful context for investors thinking about entry points. Valuation Article
• Negative Sentiment: Late‑stage trial failure for a lead indication — Rhythm reported a late‑stage weight‑loss trial setback for IMCIVREE in certain rare obesity populations, a development that previously drove shares lower and raises questions about broader label expansion and near‑term upside. Trial Failure Report
• Negative Sentiment: Multiple firms issue pessimistic forecasts / lower expectations — Bank of America and RBC published negative outlooks, and Citizens JMP and Needham also lowered expectations; these analyst moves increase downward pressure and suggest elevated near‑term volatility. Bank of America Forecast RBC Forecast Citizens JMP Needham
• Negative Sentiment: HC Wainwright lowered near‑term EPS estimate — The firm reduced its Q3 2027 EPS forecast (to $0.33 from $0.42), signaling tempered near‑term revenue/earnings visibility despite the approval and ongoing commercialization work.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.